Abbreviated eptifibatide bolus-only regimen noninferior to, safer than conventional approach
Add-on eptifibatide, infused intravenously, seems to be unnecessary for the adjunctive antithrombotic treatment during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction (STEMI), a recent study has found.
Abbreviated eptifibatide bolus-only regimen noninferior to, safer than conventional approach
11 Jan 2021